In melanoma, inhibition the FAK-paxillin interaction has been shown to be an effective therapeutic strategy, as demonstrated in several reports using site-directed mutagenesis, dominant-negative constructs, and therapeutic peptides [5,10]. Here, PXN is linked to melanoma.